ADMA Biologics Inc (NASDAQ:ADMA) Receives Consensus Rating of “Hold” from Analysts

Shares of ADMA Biologics Inc (NASDAQ:ADMA) have received an average recommendation of “Hold” from the five research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $19.00.

Several analysts recently commented on ADMA shares. Cantor Fitzgerald reiterated a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Wall Street Zen cut ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Zacks Research cut ADMA Biologics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 26th. Mizuho dropped their price target on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, Canaccord Genuity Group dropped their price target on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, May 7th.

ADMA Biologics Trading Down 1.0%

Shares of ADMA stock opened at $7.90 on Tuesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 6.95 and a quick ratio of 3.93. The company has a market cap of $1.83 billion, a price-to-earnings ratio of 11.62 and a beta of 0.83. The stock has a 50 day simple moving average of $9.60 and a 200-day simple moving average of $14.65. ADMA Biologics has a 1-year low of $7.21 and a 1-year high of $22.37.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, hitting the consensus estimate of $0.19. The business had revenue of $114.49 million during the quarter, compared to the consensus estimate of $139.98 million. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The business’s quarterly revenue was down .3% on a year-over-year basis. During the same period in the prior year, the company posted $0.11 EPS. On average, equities research analysts expect that ADMA Biologics will post 0.84 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the sale, the chief operating officer directly owned 466,600 shares in the company, valued at approximately $7,292,958. The trade was a 2.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jerrold B. Grossman purchased 12,500 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average price of $8.01 per share, with a total value of $100,125.00. Following the completion of the transaction, the director directly owned 513,884 shares of the company’s stock, valued at $4,116,210.84. This represents a 2.49% increase in their position. The disclosure for this purchase is available in the SEC filing. 3.90% of the stock is owned by company insiders.

Institutional Trading of ADMA Biologics

Several large investors have recently made changes to their positions in the company. Westfield Capital Management Co. LP purchased a new stake in ADMA Biologics in the 3rd quarter valued at $74,866,000. Janus Henderson Group PLC grew its holdings in ADMA Biologics by 3,906.1% in the 4th quarter. Janus Henderson Group PLC now owns 3,936,419 shares of the biotechnology company’s stock valued at $71,820,000 after buying an additional 3,838,158 shares in the last quarter. Capital Research Global Investors grew its holdings in ADMA Biologics by 104.0% in the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock valued at $121,067,000 after buying an additional 3,383,559 shares in the last quarter. Caligan Partners LP purchased a new stake in ADMA Biologics in the 3rd quarter valued at $38,653,000. Finally, UBS Group AG grew its holdings in ADMA Biologics by 129.9% in the 4th quarter. UBS Group AG now owns 4,569,343 shares of the biotechnology company’s stock valued at $83,345,000 after buying an additional 2,581,670 shares in the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.